AstraCe – a reliable mucolytic made by Astrapharm

World Day Against Chronic Obstructive Pulmonary Disease (COPD) is an annual event that takes place on the second or third Wednesday in November.

The main goal of this day is to draw people’s attention to interrelated problems: pulmonary pathology and smoking (including secondhand smoke), which is the main cause of the development of COPD.

Chronic obstructive pulmonary disease is a disorder characterized by persistent obstruction to airflow through the lungs that is usually only minimally reversible. The disease significantly limits the normal life of patients due to constant shortness of breath (at first occurs during exertion, and later at rest), chronic cough and sputum production.

Prevention of COPD includes:

• quitting tobacco consumption (both active and passive smoking);
• lifestyle interventions: sufficient physical activity, balanced diet, getting much fresh air;
• avoiding areas where the air is polluted;
• compliance to timely vaccination against influenza and pneumococcal infection.

Remember that COPD is a preventable and treatable disease (according to the 2019 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines).

To manage airway mucus hypersecretion in chronic diseases of the bronchopulmonary system, the pharmaceutical company Astrapharm produces the mucolytic agent AstraCe.

The active ingredient of AstraCe is acetylcysteine – an acetylated derivative of the amino acid cysteine, which reduces sputum viscosity and improves secretion clearance.

AstraCe comes in sachets each containing 200 mg of acetylcysteine, and it is recommended for use by adults and children over 2 years of age.

AstraCe has a pleasant orange taste and it is dispensed without a prescription.

Astrapharm – the art of helping people!